Literature DB >> 21924273

The coronary circulation and blood flow in left ventricular hypertrophy.

Paolo G Camici1, Iacopo Olivotto, Ornella E Rimoldi.   

Abstract

Two distinct types of left ventricular hypertrophy (LVH) have been described: the so called "physiologic" hypertrophy, which is normally found in professional athletes, and "pathologic" LVH which is found in patients with inherited heart muscle disease such as hypertrophic cardiomyopathy (HCM) or patients with cardiac and systemic diseases characterized by pressure or volume overload. Patients with pathologic LVH have often symptoms and signs suggestive of myocardial ischemia despite normal coronary angiograms. Under these circumstances ischemia is due to coronary microvascular dysfunction (CMD). The abnormalities of the coronary microcirculation may be unrelated to the degree of LVH and cause a reduction in maximum myocardial blood flow which, in the absence of epicardial stenoses, is suggestive of CMD. There is no technique that enables direct visualization of coronary microcirculation in vivo in humans. Therefore, its assessment relies on the measurement of parameters which reflect its functional status, such as myocardial blood flow and coronary flow reserve which is an integrated measure of flow through both the large epicardial coronary arteries and the microcirculation. In this review article we discuss the pathophysiological mechanisms responsible for CMD in patients with primary and secondary LVH and how the recognition of this phenomenon is providing new important information on patient stratification and prognosis. Finally, we discuss how assessment of CMD may be used as a valuable surrogate marker to test the efficacy of old and new drugs. This article is part of a Special Issue entitled "Coronary Blood Flow".
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21924273     DOI: 10.1016/j.yjmcc.2011.08.028

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  42 in total

1.  Relationship of left ventricular mass to coronary atherosclerosis and myocardial ischaemia: the CORE320 multicenter study.

Authors:  Satoru Kishi; Tiago A Magalhaes; Richard T George; Marc Dewey; Roger J Laham; Hiroyuki Niinuma; Lisa Aronson Friedman; Christopher Cox; Yutaka Tanami; Joanne D Schuijf; Andrea L Vavere; Kakuya Kitagawa; Marcus Y Chen; Cesar H Nomura; Jeffrey A Brinker; Frank J Rybicki; Marcelo F Di Carli; Armin Arbab-Zadeh; Joao A C Lima
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-11-02       Impact factor: 6.875

2.  Relationship between cardiac calcification and left ventricular hypertrophy in patients with chronic kidney disease at hemodialysis initiation.

Authors:  Ken Kitamura; Hideki Fujii; Kentaro Nakai; Keiji Kono; Shunsuke Goto; Tatsuya Nishii; Atsushi Kono; Shinichi Nishi
Journal:  Heart Vessels       Date:  2017-03-21       Impact factor: 2.037

Review 3.  Targeting the dominant mechanism of coronary microvascular dysfunction with intracoronary physiology tests.

Authors:  Hernán Mejía-Rentería; Nina van der Hoeven; Tim P van de Hoef; Julius Heemelaar; Nicola Ryan; Amir Lerman; Niels van Royen; Javier Escaned
Journal:  Int J Cardiovasc Imaging       Date:  2017-05-13       Impact factor: 2.357

Review 4.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

Review 5.  Coronary microvascular dysfunction: mechanisms and functional assessment.

Authors:  Paolo G Camici; Giulia d'Amati; Ornella Rimoldi
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

Review 6.  Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy.

Authors:  Chike C Nwabuo; Ramachandran S Vasan
Journal:  Curr Hypertens Rep       Date:  2020-02-03       Impact factor: 5.369

7.  Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.

Authors:  Rajika Roy; Maike Krenz
Journal:  J Mol Cell Cardiol       Date:  2017-09-11       Impact factor: 5.000

8.  Hypertrophic Cardiomyopathy: A Vicious Cycle Triggered by Sarcomere Mutations and Secondary Disease Hits.

Authors:  Paul J M Wijnker; Vasco Sequeira; Diederik W D Kuster; Jolanda van der Velden
Journal:  Antioxid Redox Signal       Date:  2018-04-11       Impact factor: 8.401

9.  Transcriptional network analysis for the regulation of left ventricular hypertrophy and microvascular remodeling.

Authors:  Aida Moreno-Moral; Massimiliano Mancini; Giulia D'Amati; Paolo Camici; Enrico Petretto
Journal:  J Cardiovasc Transl Res       Date:  2013-08-09       Impact factor: 4.132

10.  Interaction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease.

Authors:  Viviany R Taqueti; Brendan M Everett; Venkatesh L Murthy; Mariya Gaber; Courtney R Foster; Jon Hainer; Ron Blankstein; Sharmila Dorbala; Marcelo F Di Carli
Journal:  Circulation       Date:  2014-12-05       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.